In male mice, intra-articular PD123319 ditrifluoroacetate coadministered with monosodium urate crystals reduced nociceptive responses at 4 h and inhibited ankle edema. These findings describe an acute preventive coadministration model. [1]
During angiotensin II infusion in male LDL receptor-deficient mice, PD123319 increased ex vivo suprarenal aortic width in surviving AT2-intact and AT2-deficient animals. It did not significantly alter aortic arch area, atherosclerotic lesion area or systolic blood pressure under these conditions. [2]
Local PD123319 in an acute MSU joint-pain model
Animal study · Adult male C57BL/6/J/UFU mice, 20–25 g; local joint challenge. [1]
Coadministration reduced pain responses and ankle edema in the acute MSU model. Selected pain comparisons are at 4 h, where the viewed plots show drug-versus-MSU significance. This is prevention by coadministration, not reversal of established disease.
Conditions shared by the study groups
- Route
- Intra-articular
- Frequency
- Once, coadministered
- Treatment course
- One challenge; pain followed to 24 h, edema at 4 h
- Vehicle
- PBS
- PD123319 + MSU
- Model: Adult male C57BL/6/J/UFU mice, 20–25 g; local joint challenge.
Methods and source locations
Compound reported in the paper: PD123319 ditrifluoroacetate; Compound label in the paper: Tocris Bioscience 1361; batch 3A/189254
Reported Tocris salt in male mice; results do not validate an Adooq lot or establish clinical efficacy.
Methods 2.1–2.5, 2.8; Results 3.1–3.2; Figure 1A–C and Figure 2A.
Mechanical allodynia, spontaneous nociception and cold nociceptive responses at 4 h: Von Frey threshold, weight-bearing nociception score and acetone-evoked cold response. — Methods 2.4, 2.8; Results 3.1; Figure 1A–C and caption.
Ankle articular edema at 4 h: Plethysmometry; authors report percentage inhibition in Results 3.2. Statistical reporting: mean ± SEM. — Methods 2.5, 2.8; Results 3.2; Figure 2A and caption.
PD123319 + MSU · Methods 2.2–2.5; Figure 1A–C; Figure 2A.
PD123319 opposes local angiotensin II nociception
Animal study · Adult male C57BL/6/J/UFU mice, 20–25 g; local joint challenge. [1]
At 4 h, PD123319 coadministration prevented the mechanical allodynia caused by local angiotensin II and reduced spontaneous and cold nociceptive responses. This functional challenge supports its use as an angiotensin receptor antagonist in this model; it is not a binding/selectivity measurement.
Conditions shared by the study groups
- Route
- Intra-articular
- Frequency
- Once, coadministered
- Treatment course
- One challenge; behavior followed through 24 h; selected result at 4 h
- Vehicle
- PBS
- PD123319 + angiotensin II
- Model: Adult male C57BL/6/J/UFU mice, 20–25 g; local joint challenge.
Methods and source locations
Compound reported in the paper: PD123319 ditrifluoroacetate; Compound label in the paper: Tocris Bioscience 1361; batch 3A/189254
Reported Tocris salt in male mice; results do not validate an Adooq lot or establish clinical efficacy.
Methods 2.1–2.4, 2.8; Results 3.3; Figure 3B–D and caption.
Angiotensin II-evoked mechanical, spontaneous and cold nociceptive responses at 4 h: Von Frey threshold, weight-bearing score and acetone-evoked cold response. — Methods 2.4, 2.8; Results 3.3; Figure 3B–D.
PD123319 + angiotensin II · Methods 2.2–2.4; Results 3.3; Figure 3B–D.
AT2-independent increase in aortic expansion during angiotensin II infusion
Animal study · Male LDL receptor-deficient mice on a saturated-fat-enriched diet, with wild-type (AT2 +/y) or deficient (AT2 −/y) AT2 receptor genotype. [2]
Among surviving mice evaluated ex vivo, PD123319 increased suprarenal aortic width during AngII infusion in both AT2 genotypes, indicating that this measured expansion does not require AT2 receptors. Aortic arch area, atherosclerotic lesion area and systolic blood pressure did not change significantly with the drug. Mortality and aneurysm-incidence claims are excluded because rupture denominators are unclear.
Conditions shared by the study groups
- Route
- Subcutaneous osmotic minipump
- Frequency
- Continuous
- Treatment course
- 4 weeks
- Vehicle
- Saline reported; distinct drug stock vehicle unspecified
- AngII + PD123319, AT2 +/y
- Model: Male LDL receptor-deficient mice on a saturated-fat-enriched diet, with wild-type (AT2 +/y) or deficient (AT2 −/y) AT2 receptor genotype. Selected genotype: AT2 +/y
- Reported limits: Animal age and historical drug batch not reported in the read methods; mortality/endpoint denominators are not combined into a new estimate.
- AngII + PD123319, AT2 −/y
- Model: Male LDL receptor-deficient mice on a saturated-fat-enriched diet, with wild-type (AT2 +/y) or deficient (AT2 −/y) AT2 receptor genotype. Selected genotype: AT2 −/y
- Reported limits: Animal age and historical drug batch not reported in the read methods; mortality/endpoint denominators are not combined into a new estimate.
Methods and source locations
Compound reported in the paper: PD123319; Compound label in the paper: Sigma-Aldrich P186
Published Sigma P186 result in surviving male AngII/LDLR-deficient mice; evidence of an AT2-independent measured aortic expansion response, without a mortality or aneurysm-incidence conclusion.
Materials and Methods: Mice and Diets, minipump implantation, endpoint quantification and statistics; Results drug-co-infusion subsection; Figures 4–6; Table 2; Figure S1.
Ex vivo maximal suprarenal aortic width in surviving animals: Two-way ANOVA; individual animals, group means ± SEM shown. — Results: PD123319 Augmented AngII-induced AAAs Independent of AT2 Receptor Genotype; Figure 4A and caption.
Aortic arch intimal area, atherosclerotic lesion area and systolic blood pressure: En face area measurements and tail-cuff blood pressure; two-way ANOVA and repeated-measures ANOVA, respectively. — Results drug-co-infusion subsection; Figures 5–6 and captions; Table 2 and footnotes.
AngII + PD123319, AT2 +/y · Methods minipump/diet sections; Results drug-co-infusion subsection; Figures 4–6; Table 2.
AngII + PD123319, AT2 −/y · Methods minipump/diet sections; Results drug-co-infusion subsection; Figures 4–6; Table 2.